Pharmacogenetic testing of CYP2D6 , CYP2C19 and CYP2C9 in Denmark: Agreement between publicly funded genotyping tests and the subsequent phenotype classification
Basic & Clinical Pharmacology & Toxicology · 2024
DOI: 10.1111/bcpt.13990 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2024. Verfasst von Morten Baltzer Houlind und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Pharmacogenomic Testing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Capital Region's strategic funds, Capital Region's fund for transitional research, Danish Regions.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
- Emergency Department, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
- The Capital Region Pharmacy, Herlev, Denmark.
- Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
- Institute of Biological Psychiatry, Mental Health Centre Sct. Hans, Roskilde, Denmark.
- The Danish Epilepsy Centre, Filadelfia, Dianalund, Denmark.
ORCID-Profile: Morten Baltzer Houlind, Esben Iversen, Steffen Jørgensen, Kim Dalhoff, Per Damkier, Trine Rune Høgh Andersen, Niels Westergaard
Förderung
- The Capital Region's strategic funds
- Capital Region's fund for transitional research
- Danish Regions
- The Danish Research Unit for Hospital Pharmacy, Amgros I/S, Copenhagen, Denmark
- The Laege Sofus Carl Emil Friis og Hustru Olga Doris Friis' Legat
- Novo Nordisk Foundation
- The Læge Sofus Carl Emil Friis og Hustru Olga Doris Friis' Legat
- Novo Nordisk Fonden
Zitieren
APA
Baltzer Houlind, M., Hansen, L., Iversen, E., Rasmussen, H. B., Larsen, J. B., Jørgensen, S., Dalhoff, K., Damkier, P., Walls, A. B., Vermehren, C., Andersen, T. R. H., Kallemose, T., Christrup, L., & Westergaard, N. (2024). Pharmacogenetic testing of CYP2D6 , CYP2C19 and CYP2C9 in Denmark: Agreement between publicly funded genotyping tests and the subsequent phenotype classification. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13990
Vancouver
Baltzer Houlind M, Hansen L, Iversen E, Rasmussen HB, Larsen JB, Jørgensen S, et al. Pharmacogenetic testing of CYP2D6 , CYP2C19 and CYP2C9 in Denmark: Agreement between publicly funded genotyping tests and the subsequent phenotype classification. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.13990
BibTeX
@article{BaltzerHoulind2024,
author = {Baltzer Houlind, Morten and Hansen, Luise and Iversen, Esben and Rasmussen, Henrik Berg and Larsen, Jens Borggaard and Jørgensen, Steffen and Dalhoff, Kim and Damkier, Per and Walls, Anne B and Vermehren, Charlotte and Andersen, Trine Rune Høgh and Kallemose, Thomas and Christrup, Lona and Westergaard, Niels},
title = {Pharmacogenetic testing of CYP2D6 , CYP2C19 and CYP2C9 in Denmark: Agreement between publicly funded genotyping tests and the subsequent phenotype classification},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2024},
doi = {10.1111/bcpt.13990}
}
EUVIMED